Latest news with #AlisonHolland
Yahoo
3 days ago
- Business
- Yahoo
Medable launches programme to enhance eCOA build capabilities in clinical trials
US-based clinical technology provider Medable has launched a programme to supply contract research organisations (CROs) with generative AI-driven, electronic clinical outcome assessment (eCOA) build capabilities in digitally enabled studies. The Partner Program runs on the company's platform and aims to enable CROs to reduce clinical trial timelines by at least 50%, providing both administrative and financial benefits. It is also designed to help CROs generate trial-specific quotes rapidly and enter trial kick-off or bid defence meetings with pre-built digital studies. The Partner Program offers CROs a choice between self-service, managed service, or a hybrid support model, with the aim to deliver higher margin services through the use of generative AI. Among the programme's features are tools for pricing, demo support for bid defence meetings, and a content library to facilitate reuse and scalability. One of its key components is access to Studio, Medable's AI-powered tool for creating, storing and reusing eCOA instruments. Studio is designed to allow CROs to build eCOA assessments and deploy trials independently, providing the flexibility they need to scale their operations. Its features include content libraries, a translational workbench, virtual scheduling capabilities, and an AI-based point-and-click builder. Medable chief customer officer Alison Holland said: 'We have created a better buyer experience for CROs while putting powerful generative AI capabilities into their hands to reduce the time to first-patient-in and ensure greater control over the trial build process. 'Medable's Partner Program also simplifies administration and delivers strategic business advantages. Sponsors will want to work with our partners to move closer to Medable's vision of a one-day study start.' Based in California, Medable offers a digital clinical trials platform that has been used in nearly 400 trials across 70 countries to date. The company recently launched a digital-first long-term follow-up model intended to reduce burdens on sites and participants in cell and gene therapy trials. "Medable launches programme to enhance eCOA build capabilities in clinical trials" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Business Wire
4 days ago
- Business
- Business Wire
Medable Launches Partner Program for Faster Clinical Trial Startup, Greater Control, and Transparent Pricing
PALO ALTO, Calif.--(BUSINESS WIRE)-- Medable Inc., a leading provider of clinical development technology, today unveiled its new Partner Program, designed to empower contract research organizations (CROs) and other partners with generative AI-driven, self-service eCOA build capabilities for digitally enabled clinical trials. Leveraging the Medable platform, the program eliminates traditional bottlenecks for CROs to accelerate timelines by 50% or more, while delivering administrative and financial benefits, including straightforward, up-front pricing. Medable's Partner Program allows CROs to choose from three models – self-service, managed-service, or a hybrid of both support options. It offers pricing tools, demo support for bid defense meetings, and a portfolio content library to enable reuse and scale. The program provides partial or full enablement to help CROs take control and drive higher margin services, leveraging GenAI to help differentiate themselves in the market. Regardless of support options, the Medable Partner Program offers CROs a better, collaborative eCOA design experience for their sponsors with real-time updates. A major advantage of Medable's Partner Program is access to Studio, Medable's AI-powered solution for building, storing, and reusing eCOA instruments. Designed with CROs in mind, Studio enables self-service eCOA builds and trial deployments, giving CROs more control and flexibility to scale operations. Non-technical staff can easily build assessments in minutes for various studies and therapeutic areas with Medable Studio's rich content libraries, translational workbench, virtual scheduling, AI-based point-and-click builder, and user-friendly interface. In addition to the technical advantages of Medable Studio licensing, Medable's Partner Program simplifies the contractual relationship with upfront, consistent, and competitive pricing, streamlined communications, and on-demand support to reduce the need for change orders. The Medable Partner Program puts CROs in control to confidently: Leverage AI and automation to build higher-quality studies faster and more efficiently; Generate study-specific quotes in seconds using a self-serve pricing calculator; and, Enter any study kick-off or bid defense meeting with a pre-built digital study, ready for instant feedback and updates. 'We have created a better buyer experience for CROs while putting powerful generative AI capabilities into their hands to reduce the time to first-patient-in and ensure greater control over the trial build process,' said Alison Holland, Medable's Chief Customer Officer. 'Medable's Partner Program also simplifies administration and delivers strategic business advantages. Sponsors will want to work with our partners to move closer to Medable's vision of a one-day study start.' Medable has deployed its software-as-a-service platform in more than 300 decentralized and digitally enhanced clinical trials in 70 countries, serving more than one million patients and research participants globally. Customers have achieved impressive results – including 90% eCOA adherence and 50% cost reductions. A Tufts CSDD study also shows that, on average, decentralized trials can achieve net financial benefits from five to 13 times for Phase II and Phase III trials, equating to roughly $10 million ROI and $39 million ROI for an investment on average of $500K in Phase II and $1.5M in Phase III trials, respectively. Recently, the company launched Medable AI and Medable Studio to automatically convert outcomes assessments into fully digital eCOAs in seconds – now accessible on Google Cloud Marketplace. Today, eCOA is foundational to digitally enabled clinical trials. By leveraging Medable's AI-powered, SaaS model and new partnership efficiencies, CROs gain significant cost savings, speed, and scalability. About Medable Medable is on a mission to get effective therapies to people faster. Its digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Awarded Best Digital Health Solution by the Galien Foundation, Medable's platform has been deployed in nearly 400 trials in 70 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California, and was listed for the second year in a row on the Inc. 5000 in 2024.
